Status:
COMPLETED
Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid
Lead Sponsor:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborating Sponsors:
Kyoto University
Conditions:
Hepatitis C
Liver Cirrhosis
Eligibility:
All Genders
18-69 years
Phase:
PHASE3
Brief Summary
The aim of this study is to compare immunosuppression protocol of tacrolimus + MMF with that of tacrolimus + steroid for preventing recurrence of hepatitis C after living donor liver transplantation.
Eligibility Criteria
Inclusion
- Recipient of living donor liver transplantation for HCV-related cirrhosis
Exclusion
- ABO blood type incompatible transplant case
- Renal dysfunction (serum creatinine \>2.0 mg/dL)
- WBC \< 1,000/mm3
- Hemoglobin \< 8 g/dL
- Platelet \<30,000 /mm3
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT00469131
Start Date
September 1 2003
End Date
August 1 2011
Last Update
September 14 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kyoto University Hospital
Kyoto, Kyoto, Japan, 606-8507